Oakland, CA, United States of America

Natalia Aurrecoechea

This inventor holds 11 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Nektar Therapeutics, Novartis Vaccines & Diagnostics, Gmbh, Telik, Inc.. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Natalia Aurrecoechea. Retrieved from https://idiyas.com/inventor/natalia-aurrecoechea

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 36.4

 

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2006-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Inventor Natalia Aurrecoechea: Revolutionizing Technology

Introduction: Natalia Aurrecoechea is a pioneering inventor based in Oakland, CA, known for her groundbreaking contributions to the field of technology.

Latest Patents: Natalia Aurrecoechea holds several patents in the areas of artificial intelligence, renewable energy, and sustainable materials, showcasing her diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Natalia has worked with leading tech companies to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout her career, Natalia has collaborated with top researchers, engineers, and scientists to bring her inventions to life, fostering a culture of innovation and creativity.

Conclusion: Natalia Aurrecoechea's relentless pursuit of innovation and her passion for creating a better future through technology make her a true visionary in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…